Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs ArcelorMittal SA — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.28 (market cap $12.58B), while ArcelorMittal SA trades at $64.29 (market cap $45.70B). The key difference: ArcelorMittal SA is far larger — about 3.6× Halozyme Therapeutics Inc. Common Stock's market cap, and ArcelorMittal SA pays a 0.98% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and ArcelorMittal SA for 36 Days on average.
| HALO | MT | |
|---|---|---|
Market Cap | $12.58B | $45.70B |
Volume | 2,179,278 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $115.22 | $78.74 |
52-Week Low | $61.63 | $36.91 |
Typical Hold Time | 1 Days | 36 Days |
Enterprise Value | $14.49B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $64.18, up 2.98% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains solid fundamentals with a P/E of 25.76 and P/S of 0.75, though recent Q2 2026 earnings missed expectations. Revenue has declined from $79.8B in 2022 to $61.4B in 2025, while net income improved to $3.2B. Recent news highlights operational challenges in Ukraine with a $1B impairment charge, but strategic partnerships and European demand improvements provide offsetting positives.
The outlook remains cautiously optimistic with analyst consensus price target of $74.33 representing 16% upside potential. Key opportunities include expanding steel capacity and regionalization benefits, while risks involve ongoing Ukraine operations disruption, China demand weakness, and elevated capital expenditures. Institutional sentiment leans bullish with 52% buy ratings, though technical resistance near $62-63 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
